FDA
Tecentriq/Arbaxane Combo Becomes the First FDA Approved Immunotherapy Regimen for Breast Cancer Treatment
2019-03-14
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
LATEST
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115